Cancer false alarm may give false sense of security
the ONA take:
According to a new study published in the journal BMJ Open, Cancer Research UK researchers have found that having a cancer false alarm could dissuade people from further investigating cancer symptoms they may develop in the future.
Researchers from the Health Behaviour Research Centre at University College London in United Kingdom conducted a review of 19 international studies to assess the effect of a cancer false alarm.
They found that patients may delay seeking help from a healthcare professional for new or recurrent symptoms if they feel that it is not cancer because of a previous false alarm or if they feel unsupported by the healthcare system.
Researchers found that if patients felt unsupported previously, there is a concern that the healthcare professional will think the patient is making a fuss out of nothing.
Results also showed that insufficient education at the time of the cancer false alarm made the patients feel like the doctor would not be able to help at the time of new onset of symptoms.
The findings suggest that patients should not have a false sense of security after experiencing a cancer false alarm, and that patients should still seek help from a healthcare professional if the experience new or recurrent symptoms.
Having a cancer false alarm could dissuade people from further investigating cancer symptoms they may develop in the future.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|